Triglav Skladi D.O.O. Makes New $1.59 Million Investment in Incyte Co. (NASDAQ:INCY)

Triglav Skladi D.O.O. acquired a new stake in Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,000 shares of the biopharmaceutical company's stock, valued at approximately $1,589,000.

A number of other institutional investors have also bought and sold shares of INCY. Norges Bank purchased a new stake in shares of Incyte in the fourth quarter valued at about $121,890,000. AQR Capital Management LLC boosted its holdings in Incyte by 29.7% in the 4th quarter. AQR Capital Management LLC now owns 3,502,813 shares of the biopharmaceutical company's stock valued at $241,519,000 after purchasing an additional 801,090 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Incyte by 861.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 891,659 shares of the biopharmaceutical company's stock valued at $61,587,000 after purchasing an additional 798,877 shares during the last quarter. Sound Shore Management Inc. CT boosted its holdings in Incyte by 98.4% in the 4th quarter. Sound Shore Management Inc. CT now owns 1,201,089 shares of the biopharmaceutical company's stock valued at $82,959,000 after purchasing an additional 595,741 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in Incyte by 73.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,313,873 shares of the biopharmaceutical company's stock valued at $90,749,000 after purchasing an additional 556,218 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Stock Down 0.4%

NASDAQ:INCY traded down $0.27 during trading hours on Thursday, reaching $64.51. The company's stock had a trading volume of 1,557,140 shares, compared to its average volume of 2,316,761. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The company has a market cap of $12.49 billion, a price-to-earnings ratio of 238.93, a price-to-earnings-growth ratio of 0.41 and a beta of 0.68. Incyte Co. has a one year low of $53.56 and a one year high of $83.95. The business's 50-day moving average is $60.30 and its 200-day moving average is $68.26.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating the consensus estimate of $1.01 by $0.15. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $996.17 million. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The company's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.64 earnings per share. Equities research analysts predict that Incyte Co. will post 4.86 EPS for the current year.

Insider Transactions at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,809,101.52. The trade was a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. This represents a 37.11% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,475 shares of company stock worth $2,424,751. Insiders own 17.80% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Incyte from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 30th. William Blair cut shares of Incyte from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 18th. Wells Fargo & Company increased their price objective on shares of Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Truist Financial lowered their price objective on shares of Incyte from $74.00 to $72.00 and set a "hold" rating for the company in a research report on Tuesday, March 18th. Finally, Morgan Stanley lowered their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, March 24th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $73.53.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.